You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. MK III Upper Extremity Exoskeleton

    SBC: Ekso Bionics Inc            Topic: 739552

    As the carry and protective gear of the modern war fighter increases, the burden on the human body will necessarily increase. In our present TALOS MkIII project, we are developing lower body augmentation to preserve speed and agility while bearing this weight. Yet we cannot ignore the impact of this weight on the upper body: in this project we propose to develop an upper body exoskeleton with p ...

    STTR Phase II 2015 Department of DefenseSpecial Operations Command
  2. Information Salience

    SBC: DISCERNING TECHNOLOGIES, LLC            Topic: OSD11TD1

    Empirical-based mathematical framework and computer algorithms, for representing human perception and cognition processes and limitations, which influence the recognition of salient information about rapidly changing events.

    STTR Phase II 2015 Department of DefenseOffice of the Secretary of Defense
  3. Data Driven Intent Recognition Framework

    SBC: Other Lab Inc.            Topic: NSF13599

    A critical aspect of exoskeleton control that has to date introduced a performance limitation is the ability of the exoskeleton to recognize the intent of the operator so it can apply assistance to their desired motion. This intent recognition effort is typically solved using ad-hoc methods where subject matter experts make design decisions and tune transitions to identify intended maneuvers as re ...

    STTR Phase II 2016 Department of DefenseSpecial Operations Command
  4. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  6. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  7. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GeneCapture, Inc.            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government